Integra LifeSciences Holdings Corporation — Q3 2010 Form 10-Q
Reporting period: Three and nine months ended September 30, 2010; filed October 28, 2010. Integra develops, manufactures, and markets medical devices for orthopedics, neurosurgery, instruments, tissue repair, and related procedures. The company reports one operating segment.
Financial performance and liquidity
| Metric | Q3 2010 | Q3 2009 | 9M 2010 | 9M 2009 |
|---|---|---|---|---|
| Revenue | $186.6 million | $172.3 million | $537.9 million | $499.0 million |
| Gross margin | $117.4 million; 62.9% | $109.3 million; 63.4% | $341.1 million; 63.4% | $318.0 million; 63.7% |
| Operating income | $27.3 million | $23.8 million | $74.5 million | $70.0 million |
| Net income | $16.5 million | $14.4 million | $46.9 million | $35.2 million |
| Diluted EPS | $0.55 | $0.49 | $1.54 | $1.20 |
| Cash flow from operations | Not provided for the quarter | Not provided for the quarter | $77.1 million | $96.2 million |
- Q3 revenue increased 8.3%; nine-month revenue increased 7.8%. Orthopedics was the largest growth driver, increasing 13.7% in Q3 and 11.5% year to date. Neurosurgery increased 3.9% in Q3 and 6.6% year to date; Instruments increased 7.2% and 3.6%, respectively.
- Q3 operating margin was approximately 14.6%, versus 13.8% in the prior-year quarter. Nine-month operating margin was approximately 13.9%, versus 14.0% in 2009.
- Q3 net margin was approximately 8.8%, versus 8.4% in Q3 2009. Nine-month net margin was approximately 8.7%, versus 7.1% in 2009.
- Interest expense declined to $4.4 million in Q3 and $13.2 million for nine months, primarily following repayment of the 2010 convertible notes.
- Cash and cash equivalents were $82.8 million at September 30, 2010, compared with $71.9 million at December 31, 2009. Working capital was $283.6 million, compared with $208.6 million at year-end.
- Operating cash flow declined year over year despite higher earnings, principally because accounts receivable and inventories used cash and long-term liabilities decreased.
- Investing cash outflows were $23.1 million, including $18.9 million of capital expenditures and $4.2 million for acquisitions. Financing cash outflows were $40.2 million, including $71.4 million to repay the 2010 notes and $31.3 million of share repurchases, partly offset by $60.0 million of net credit-facility borrowings.
Debt, capital resources, and material changes
- In August 2010, Integra amended and restated its senior credit facility, increasing total commitments to $600.0 million, including a $150.0 million term loan, and extending maturity to August 2015. Approximately $380.0 million was available at September 30.
- At September 30, borrowings under the senior credit facility totaled $220.0 million, consisting of $150.0 million of term debt and $70.0 million drawn on the revolving facility. The company also had $165.0 million of 2012 senior convertible notes outstanding.
- The 2010 convertible notes were repaid in full in June 2010. Subsequent to quarter-end, on October 19, the company borrowed an additional $30.0 million; outstanding senior-facility borrowings were therefore $250.0 million as of the filing date.
- The company repurchased $31.3 million of common stock during the first nine months under a $75.0 million authorization expiring December 31, 2010.
- Acquisitions included the Welch Allyn surgical headlight business for approximately $2.6 million, including working-capital adjustments, and Australian extremity-reconstruction distribution assets from Culley for approximately $1.6 million.
Outlook, commentary, risks, and unusual items
- Management expects growth from new products, acquisitions, broader sales coverage, and operational efficiencies. No specific revenue or earnings-per-share guidance was provided.
- Management targeted 2010 research and development spending at approximately 6.5% of revenue, selling, general and administrative spending at approximately 41.5% of revenue, and a full-year effective tax rate of approximately 26.25%.
- Management expects gross-margin improvement over time from revenue growth, manufacturing efficiencies, inventory management, and a greater mix of higher-margin implant products, but near-term margin pressure remains from production and engineering costs and product mix.
- Reported 2010 results included acquisition, integration, restructuring, facility, employee-termination, and brand-impairment charges. Total identified charges were $12.7 million for the first nine months, compared with $16.8 million in 2009. Management stated that similar charges may recur.
- A seller’s representative in the Theken acquisition alleges an additional $6.7 million earn-out obligation. Integra accrued $3.4 million and believes no additional amount is due for the second performance year.
- Key risks include healthcare-cost containment and reimbursement reductions, foreign-exchange exposure, regulatory approvals and FDA compliance, product recalls or field corrections, manufacturing disruptions, supply-chain and geopolitical risks, acquisition integration, interest-rate exposure, and pricing pressure in Europe and other international markets.
- An interest-rate swap with a $148.1 million notional amount begins fixing a portion of floating-rate debt effective December 31, 2010. A 1% increase in rates would have increased annualized interest expense on the unhedged debt by approximately $2.2 million based on September 30 borrowings.
- Subsequent events included the appointment of Peter J. Arduini as President and Chief Operating Officer effective November 1, 2010, amended executive employment arrangements, and expected additional fourth-quarter compensation costs of approximately $2.0 million.
Investor verification points
- Reconcile the October 19 post-quarter-end borrowing and its effect on leverage, covenant headroom, liquidity, and interest expense.
- Monitor the Theken earn-out dispute and whether the $3.4 million accrual adequately covers the potential $6.7 million claim.
- Assess whether revenue growth can offset slightly lower gross margins and increased selling, general and administrative costs.
- Verify working-capital trends, particularly inventory and accounts receivable, given the year-over-year decline in operating cash flow.
- Evaluate reimbursement changes affecting wound-dressing products, the potential 2013 medical-device excise tax, and broader healthcare pricing pressure.
- Review future brand-impairment, restructuring, acquisition-integration, and manufacturing-transfer charges, which management indicates may recur.